HC Wainwright Lowers Vor Biopharma (NYSE:VOR) Price Target to $13.00

Vor Biopharma (NYSE:VOR) had its price objective cut by investment analysts at HC Wainwright from $17.50 to $13.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other brokerages have also recently weighed in on VOR. JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of Vor Biopharma in a report on Thursday. Finally, Stifel Nicolaus lowered their price target on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma presently has an average rating of “Buy” and a consensus target price of $9.14.

Vor Biopharma Stock Up 0.9 %

Vor Biopharma stock opened at $0.85 on Friday. The firm has a market cap of $58.51 million, a P/E ratio of -0.52 and a beta of -0.40. The business has a fifty day moving average of $1.23 and a two-hundred day moving average of $1.01. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $2.43.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors have recently added to or reduced their stakes in VOR. Two Sigma Investments LP increased its holdings in shares of Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after acquiring an additional 25,930 shares in the last quarter. Northern Trust Corp increased its stake in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares in the last quarter. Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma in the fourth quarter worth $102,000. RA Capital Management L.P. lifted its stake in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after buying an additional 16,897,159 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at $80,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.